Glycolysis in panc-1 human pancreatic cancer cells is inhibited by everolimus

Experimental and Therapeutic Medicine

Volumn 5, Issue 1, 2013, Pages 338-342

  Liu, Ling ^a   Gong, Liansheng ^a   Zhang, Yangde ^a   Li, Nianfeng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Everolimus; Glycolysis; Panc 1 cells; Pancreatic cancer

Indexed keywords

EVEROLIMUS; HEXOKINASE; HEXOKINASE 2; LACTATE DEHYDROGENASE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 143; S6 KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; LACTATE BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; PANCREAS CANCER; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84869416107     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.787     Document Type: Article

References (37)

1. Saif MW: Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP 8: 545-552, 2007.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
3. Bayley JP and Devilee P: The Warburg effect in 2012. Curr Opin Oncol 24: 62-67, 2012.
4. Dang CV: Links between metabolism and cancer. Genes Dev 26: 877-890, 2012.
5. Ponisovskiy MR: Warburg effect mechanism as the target for theoretical substantiation of a new potential cancer treatment. Crit Rev Eukaryot Gene Expr 21: 13-28, 2011.
6. Paez D, Labonte MJ and Lenz HJ: Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am 41: 189-209, 2012.
7. Benjamin D, Colombi M, Moroni C and Hall MN: Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10: 868-880, 2011.
8. Oberstein PE, Remotti H, Saif MW and Libutti SK: Pancreatic neuroendocr ine tumors: enter ing a new era. JOP 13: 169-173, 2012.
9. Schwarzlose-Schwarck S, Scholz CW, Regierer AC, et al: The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer - a phase I trial. Anticancer Res 32: 3435-3441, 2012.
10. Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, et al: Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines. J Toxicol Environ Health A 75: 788-799, 2012.
11. Tomioka H, Mukohara T, Kataoka Y, et al: Inhibition of the mTOR/S6K signal is necessary to enhance fuorouracil-induced apoptosis in gastric cancer cells with HER2 amplifcation. Int J Oncol 41: 551-558, 2012.
12. Tai S, Sun Y, Liu N, et al: Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther 11: 1320-1331, 2012.
13. Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E and Kakolyris S: Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology 81: 259-272, 2011.
14. Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell 149: 274-293, 2012.
15. Magnuson B, Ekim B and Fingar DC: Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441: 1-21, 2012.
16. Populo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci 13: 1886-1918, 2012.
17. Iwase Y and Maitani Y: Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma. Biol Pharm Bull 35: 975-979, 2012.
18. Mathupala SP, Ko YH and Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777-4786, 2006.
19. Wolf A, Agnihotri S, Micallef J, et al: Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208: 313-326, 2011.
20. Fang R, Xiao T, Fang Z, et al: MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem 287: 23227-23235, 2012.
21. Akao Y, Nakagawa Y and Naoe T: MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 16: 845-850, 2006.
22. Li X, Zhang G, Luo F, et al: Identifcation of aberrantly expressed miRNAs in rectal cancer. Oncol Rep 28: 77-84, 2012.
23. White NM, Youssef YM, Fendler A, Stephan C, Jung K and Yousef GM: The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biol Chem 393: 379-389, 2012.
24. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T and Naoe T: Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 98: 1914-1920, 2007.
25. Chen HC, Chen GH, Chen YH, et al: MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 100: 1002-1011, 2009.
26. Wang X, Tang S, Le SY, et al: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3: e2557, 2008.
27. Amaral FC, Torres N, Saggioro F, et al: MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab 94: 320-323, 2009.
28. Yu T, Wang XY, Gong RG, et al: The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res 28: 64, 2009.
29. Motoyama K, Inoue H, Takatsuno Y, et al: Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 34: 1069-1075, 2009.
30. Chen X, Guo X, Zhang H, et al: Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28: 1385-1392, 2009.
31. Ng EK, Tsang WP, Ng SS, et al: MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 101: 699 -706, 2009.
32. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ and Rodrigues CM: MicroRNA-143 reduces viability and increases sensitivity to 5-fuorouracil in HCT116 human colorectal cancer cells. FEBS J 276: 6689-6700, 2009.
33. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP and James RJ: Reduced accumulation of specifc microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891, 2003.
34. Zhang Y, Wang Z, Chen M, et al: MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer 11: 23, 2012.
35. Liu L, Yu X, Guo X, et al: miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Report 5: 753-760, 2012.
36. Jiang S, Zhang LF, Zhang HW, et al: A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 31: 1985-1998, 2012.
37. Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A and Lund AH: microRNA-143 down-regulates Hexokinase 2 in colon cancer cells. BMC Cancer 12: 232, 2012.